Please login to the form below

Not currently logged in

Takeda launches new business in China

Will serve as hub for importing medicines from across the world

Takeda has launched a new division in China to serve as a hub for importing the company's products from its manufacturing sites across the world.

The establishment of Takeda (China) International Trading (TCIT) follows the Japan-based company's decision last year that it would invest in emerging markets to cope with the loss of patent protection for its blockbuster diabetes drug Actos (pioglitazone).

Takeda had already made headway in China before that announcement through its 2011 purchase of Nycomed, which operated in the country through its Nycomed Shanghai business and its 2010 acquisition of Guangdong Techpool Bio-Pharma.

TCIT will begin operations this month, with 500 employees of Nycomed Shanghai to be transferred to the new business and other operations owned by Takeda in China.

Following this restructure, Nycomed Shanghai is then due to be liquidated by the end of March 2015.

“Our new business structure will simplify our distribution processes and improve our efficiency to better serve patients in this huge and important market,” said Haruhiko Hirate, corporate officer and head of North Asia of Takeda.

“In conjunction with the recent opening of our development centre in Shanghai, we are now best equipped to bring new products to Chinese patients as early as possible.”

According to Takeda, China is currently the company's seventh largest market with top line growth expected to grow by a compound annual growth rate (CAGR) of 29 per cent between the financial years 2012 and 2016.

In addition to its Nycomed purchase, other recent investments in the area include the announcement last year it intended to create the Takeda Shanghai Development Center to expand the company's clinical development activities in Asia. In 2010, Takeda also expanded both its manufacturing and sales activities by taking full control of Tianjin Takeda - formerly a part-owned joint venture.

23rd January 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....